Diazepam-binding inhibitor and corticotropin-releasing hormone in cerebrospinal fluid

A. Roy, D. Pickar, P. Gold, M. Barbaccia, A. Guidotti, E. Costa, M. Linnoila

Research output: Contribution to journalArticle

Abstract

Diazepam-binding inhibitor (DBI) is a neuromodulatory peptide for gamma-aminobutyric acid (GABA) neurotransmission. Cerebrospinal fluid (CSF) levels of DBI have been found to be elevated in depression. CSF levels of the peptide corticotropin-releasing hormone (CRH) have also been found to be elevated in depression. Therefore, we examined for a relationship between DBI and CRH in human CSF. We found significant positive correlations between CSF levels of DBI and CRH in depressed patients, pathological gamblers, and normal controls. These data, along with the elevated CSF levels of DBI in depression, suggest the possibility that DBI may have a role in coordinating responses to stress in humans in addition to its possible role in the pathophysiology of depression.

Original languageEnglish (US)
Pages (from-to)287-291
Number of pages5
JournalActa Psychiatrica Scandinavica
Volume80
Issue number3
StatePublished - 1989
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Diazepam-binding inhibitor and corticotropin-releasing hormone in cerebrospinal fluid'. Together they form a unique fingerprint.

  • Cite this

    Roy, A., Pickar, D., Gold, P., Barbaccia, M., Guidotti, A., Costa, E., & Linnoila, M. (1989). Diazepam-binding inhibitor and corticotropin-releasing hormone in cerebrospinal fluid. Acta Psychiatrica Scandinavica, 80(3), 287-291.